The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 1 - Any |
| Updated: | 1/6/2018 |
| Start Date: | January 1995 |
| End Date: | December 2020 |
| Contact: | Mayu Frank, NP |
| Email: | frankm@rockefeller.edu |
| Phone: | 212-327-7454 |
Killer T Cell Activity in the Paraneoplastic Neurologic Syndromes
The investigators believe that T cells, cells that are a part of the immune system, are what
are causing the neurological problems while also attacking tumor cells. This protocol studies
the clinical status of patients with paraneoplastic neurological disorder (PND) as well as
their blood to understand the relationship between their neurological disease, their cancer,
and their immune system.
are causing the neurological problems while also attacking tumor cells. This protocol studies
the clinical status of patients with paraneoplastic neurological disorder (PND) as well as
their blood to understand the relationship between their neurological disease, their cancer,
and their immune system.
Patients with paraneoplastic neurological disorders (PNDs) provide a unique model for
studying tumor immunity and neuronal autoimmunity. We hypothesize that T lymphocyte
autoimmune dysfunction is involved in the pathogenesis of the paraneoplastic neurological
syndromes, and that killer T cells are involved in the targeting and successful killing of
tumor cells in these cancer patients. Furthermore, we postulate that this activity may
provide a model for autoimmune brain disease. We will assess the immune responses in PND
patients, correlate these with the clinical data (time course of disease, symptoms and signs,
disability), and collect and archive clinical data, serum and cells from PND patients for
current and future studies into the basic immune system phenomenon present in PND patients.
studying tumor immunity and neuronal autoimmunity. We hypothesize that T lymphocyte
autoimmune dysfunction is involved in the pathogenesis of the paraneoplastic neurological
syndromes, and that killer T cells are involved in the targeting and successful killing of
tumor cells in these cancer patients. Furthermore, we postulate that this activity may
provide a model for autoimmune brain disease. We will assess the immune responses in PND
patients, correlate these with the clinical data (time course of disease, symptoms and signs,
disability), and collect and archive clinical data, serum and cells from PND patients for
current and future studies into the basic immune system phenomenon present in PND patients.
Inclusion Criteria:
- Neurological disease which is suspected to be paraneoplastic
- No known active additional malignancy other than non-melanoma skin cancer
Exclusion Criteria:
- Known central nervous system (CNS) metastasis
- Known active additional malignancy
- No pulmonary disease which limits daily activities
if leukapheresis: must be 14 or older no known hepatitis B or C, HIV, or syphilis (by
history or prior negative tests) no known IV drug users HgB > 8.5 WBC > 3,500 platelets >
100,000 INR < 2
if large blood draw (1/2 to 1 unit; children 3 ml/kg) in lieu of leukapheresis: no known IV
drug users HgB > 10 WBC > 3,500 platelets > 100,000 INR < 2
if lumbar puncture: platelets > 120,000 INR < 1.2 must be 14 or older
We found this trial at
1
site
New York, New York 10021
Principal Investigator: Robert Darnell, MD, PHD
Phone: 212-327-7443
Click here to add this to my saved trials
